info@seagull-health.com
SeagullHealth
语言:
search
new
Indications for Meloxicam
505
Article source: Seagull Pharmacy
Nov 10, 2025

Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) first approved for marketing in the United States in 2000. As a potent inhibitor of cyclooxygenase (COX-1 and COX-2), it exerts analgesic, anti-inflammatory, and antipyretic effects by blocking the production of prostaglandins during the inflammatory process.

Indications for Meloxicam

Therapeutic Areas in Adults

Meloxicam is primarily indicated for the treatment of osteoarthritis (OA) and rheumatoid arthritis (RA) in adults.

For osteoarthritis, this medication effectively relieves symptoms such as joint pain, stiffness, and functional impairment.

In the treatment of rheumatoid arthritis, Meloxicam can significantly improve key indicators including morning stiffness duration, joint swelling, and pain scores.

Indications in Pediatric Patients

Meloxicam is also indicated for adolescent patients with juvenile rheumatoid arthritis (JRA) who have a body weight of ≥ 60 kg, specifically targeting patients with oligoarticular or polyarticular disease course.

Contraindications for Use

Patients with a known allergy to Meloxicam or any component of the medication.

Patients with a history of asthma, urticaria, or other allergic-type reactions.

Patients in the perioperative period of coronary artery bypass grafting (CABG) surgery.

Specifications and Properties of Meloxicam

Dosage Specifications

Meloxicam is available as pale yellow tablets in two strengths: 7.5 mg and 15 mg.

The 7.5 mg tablets are round, biconvex, and uncoated. One side is embossed with the Boehringer Ingelheim logo, and the other side is embossed with the letter "M".

The 15 mg tablets are oval, biconvex, and uncoated. One side is embossed with the number "15", and the other side is embossed with the letter "M".

Drug Composition

Active ingredient: Meloxicam. Its chemical name is 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide, with a molecular weight of 351.4.

Molecular formula: C₁₄H₁₃N₃O₄S₂.

Excipients: Colloidal silicon dioxide, crospovidone, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone, and sodium citrate dihydrate.

Physicochemical Properties

Meloxicam is a pale yellow solid. It is practically insoluble in water, highly soluble in strong acids and strong alkalis, and slightly soluble in methanol.

The apparent partition coefficient of this substance in n-octanol/buffer (pH 7.4) is 0.1, and its pKa values are 1.1 and 4.2.

Storage Methods for Meloxicam

Storage Environment Requirements

Meloxicam should be stored at room temperature between 20°C and 25°C (68°F and 77°F), with short-term storage allowed within the range of 15°C to 30°C (59°F to 86°F).

Packaging Protection Measures

The medication must be stored in its original packaging.

Store in a dry place: Ensure the storage environment is dry.

Airtight container: Use sealed containers for repackaging (if necessary).

Protect from light: Prevent direct exposure to sunlight.

Handling Precautions

Always keep the tablets in their original moisture-proof packaging.

Remove from the packaging only before the first use.

Keep out of the reach of children to ensure safe storage of the medication.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Recommended Articles
How to Purchase Meloxicam
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of osteoarthritis (OA), rheumatoid arthritis (RA), and juvenile idiopathic arthritis (JRA) in patients with a bod...
Standard Usage Instructions
Wayrilz (Rezabrutinib) is a kinase inhibitor that primarily acts on Bruton's Tyrosine Kinase (BTK). First approved in the United States in 2025, this medication is indicated for the treatment of p...
Indications for Wayrilz (Rezabrutinib)
Wayrilz (Rezabrutinib) is a novel kinase inhibitor, first approved for marketing in the United States in 2025. As a small-molecule covalent reversible inhibitor targeting Bruton's Tyrosine Kinase ...
What Are the Side Effects of Trelegy Ellipta (Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol Trifenatate Inhalation Powder)?
Trelegy Ellipta (Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol Trifenatate Inhalation Powder) is a triple-combination therapy medication containing fluticasone furoate (an inhaled corticos...
Administration for Meloxicam
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic effects. First approved in the United States in 2000, it is indicated for the treatment of...
Indications for Trelegy Ellipta (Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol Trifenatate Inhalation Powder)
Trelegy Ellipta (Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol Trifenatate Inhalation Powder) is a triple-combination preparation containing fluticasone furoate (an inhaled corticosteroid)...
How to Purchase Wayrilz (Rezabrutinib)
Wayrilz (Rezabrutinib) is a novel Bruton's Tyrosine Kinase (BTK) inhibitor. Approved in the United States in 2025, it is indicated for the treatment of persistent or chronic immune thrombocytopeni...
What Are the Side Effects of Wayrilz (Rezabrutinib)?
Wayrilz (Rezabrutinib) is an oral Bruton's Tyrosine Kinase inhibitor. Approved by the U.S. FDA in 2025, it is indicated for the treatment of persistent or chronic immune thrombocytopenia in adults...
Related Articles
Dosage and Administration, Precautions, and Healthy Lifestyle for Cenobamate
Cenobamate is a novel once-daily oral antiepileptic drug. Correct dosage and administration, strict adherence to precautions, and a healthy lifestyle are critical to ensuring its efficacy and safety.I...
Side Effects of Cenobamate and Management Strategies
Cenobamate is an effective novel antiepileptic drug, but it is associated with a range of side effects.I. Side Effects of Cenobamate1. Most Common Side Effects (Incidence ≥10% and higher than placebo)...
Safinamide (Xadago): Domestic Launch and Purchase Guide in China
As an adjunctive treatment for Parkinson’s disease, the accessibility of safinamide in China is a major concern for patients.I. Domestic Launch Status1. Not Yet Launched in Chinese Mainland(1) As of A...
Analysis of the Therapeutic Value and Accessibility of Safinamide (Xadago)
As an adjunctive treatment for "off" episodes in Parkinson’s disease, safinamide’s clinical efficacy, medical insurance coverage, and pricing are common concerns for patients and their famil...
Dosage and Administration, Precautions, and Healthy Living Guidelines for Anagrelide (Agrylin)
Anagrelide is a prescription platelet-lowering medication that must be used precisely under the guidance of a physician.I. Dosage and Administration1. Adult Starting Dose(1) The recommended starting d...
Anagrelide (Agrylin): Side Effects, Management Strategies and Storage Guidelines
Anagrelide is a platelet-lowering agent with well-established efficacy, yet it is associated with a variety of adverse reactions.I. Common Side Effects1. Adverse Reactions with an Incidence Rate ≥ 5%T...
Drug Overview and Administration Guidance for Topiroxostat
Topiroxostat is a non-purine selective xanthine oxidase inhibitor indicated for the treatment of gout and hyperuricemia.I. Pharmaceutical Properties and Mechanism of Action1. Active Ingredient and Dos...
Key Clinical Application Guidelines for Topiroxostat
Topiroxostat is a non-purine selective xanthine oxidase inhibitor that exerts a uric acid-lowering effect by inhibiting uric acid production.I. Indications and Target Population1. Approved Indications...
New Drugs
Infigratinib(Truseltiq)
Infigratinib(Truseltiq)
Treatment of previously treated, unresectable locally advanced or metastatic...
Opicapone(Ongentys)
Opicapone(Ongentys)
Adjunctive treatment to levodopa/carbidopa for reducing "off" episodes in...
Deflazacort(Emflaza)
Deflazacort(Emflaza)
Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and...
Faricimab-svoa(Vabysmo)
Faricimab-svoa(Vabysmo)
Treatment of neovascular age-related macular degeneration, diabetic macular...
Counselling Service
Global Drug Search
Clinical Research Recruitment
Overseas Medical Treatment
Remote Consultations
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Submit
Business
  • Core products
  • Antitumor drugs
  • General drug
  • Antiviral drugs
  • Biological agents
Contact Us 
  • haiousales@gmail.com
Welcome to consult
Seagull Pharmacy.,Ltd All rights reserved